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Introduction Major depressive disorder (MDD) is a 
chronic condition. Although current treatment approaches 
are effective in reducing acute depressive symptoms, 
rates of relapse are high. Chronic and inflexible retrieval 
of autobiographical memories, and in particular a bias 
towards negative and overgeneral memories, is a reliable 
predictor of relapse. This randomised controlled single-
blind trial will determine whether a therapist-guided self-
help intervention to ameliorate autobiographical memory 
biases using Memory Flexibility training (MemFlex) will 
increase the experience of depression-free days, relative 
to a psychoeducation control condition, in the 12 months 
following intervention.
Methods and analysis Individuals (aged 18 and above) 
with a diagnosis of recurrent MDD will be recruited when 
remitted from a major depressive episode. Participants will 
be randomly allocated to complete 4 weeks of a workbook 
providing either MemFlex training, or psychoeducation 
on factors that increase risk of relapse. Assessment of 
diagnostic status, self-report depressive symptoms, 
depression-free days and cognitive risk factors for 
depression will be completed post-intervention, and 
at 6 and 12 months follow-up. The cognitive target of 
MemFlex will be change in memory flexibility on the 
Autobiographical Memory Test- Alternating Instructions. 
The primary clinical endpoints will be the number of 
depression-free days in the 12 months following workbook 
completion, and time to depressive relapse.
Ethics and dissemination Ethics approval has been 
granted by the NHS National Research Ethics Committee 
(East of England, 11/H0305/1). Results from this study 
will provide a point-estimate of the effect of MemFlex on 
depressive relapse, which will be used to inform a fully 
powered trial evaluating the potential of MemFlex as an 
effective, low-cost and low-intensity option for reducing 
relapse of MDD.
trial registration number NCT02614326.
IntroduCtIon 
Depression is a recurrent and pervasive 
condition which dramatically reduces quality 
of life for the individual and costs the health 
system in the UK an estimated £7.5 billion per 
year.1 Although psychological approaches to 
treating depression are effective in reducing 
current symptoms,2 relapse rates are high. 
On average, those with major depressive 
disorder (MDD) will experience 10 separate 
depressive episodes across their lifespan,3 and 
symptom severity increases with each experi-
enced episode.4 As such, reducing depressive 
relapse is a key challenge for health systems. 
Broadly, depressive risk is increased by the 
chronic use of maladaptive cognitive styles 
which promote depressogenic thoughts, attri-
butions and beliefs,5 thus, intervention to 
reduce the chronicity of these cognitive styles 
may thereby break the vicious cycle of depres-
sion. Importantly, as cognitive risk factors 
for depression remain evident when depres-
sive symptoms remit, it may be possible to 
complete interventions to shift these factors 
when the individual is psychologically well, 
and more able to engage in therapy. Further 
exploration of low-cost and low-intensity 
options for reducing these cognitive risk 
factors may have important implications for 
strengths and limitations of this study
 ► This early-stage platform trial seeks to establish an 
estimate of effect size to power a later-stage trial.
 ► The intervention condition will be compared with an 
active control condition.
 ► The hard-copy workbook format limits the ability 
to track completion of the intervention sessions in 
real time.
 ► The absence of booster sessions following workbook 
completion may limit the long-term efficacy of the 
intervention.
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limiting depressive relapse and subsequent costs for the 
individual and healthcare system. This trial will investi-
gate the efficacy of a low-intensity programme, Memory 
Flexibility training (MemFlex), which aims to reduce one 
such risk factor—inflexible retrieval of autobiographical 
memories.
Autobiographical memory, that is, memory of 
personal life experiences, is integral in forming 
one’s sense of self,6 and disruptions in autobiograph-
ical memory increase risk of depression (for review 
see ref7). Autobiographical information is stored in 
a fluid manner, and can therefore be retrieved in a 
variety of formats, including as specific, single incident 
events that are rich in detail (eg, when I forgot my 
purse and couldn’t buy my train ticket), or as general-
isations that summarise consistency across a category 
of events (eg, catching the train to work every day). 
Memory flexibility refers to the ability to successfully 
navigate the autobiographical information database 
to deliberately retrieve memories varying in detail and 
emotional valence. In depression, flexible movement 
within the autobiographical information database 
is compromised,8 9 resulting in relative difficulties in 
retrieving both general and specific memories.8 10 11 
This can create functional impairment as both types 
of memory are necessary in daily cognitive skills; for 
example, specific memories can help to guide problem 
solving12 while general memories encode regularities 
of experiences that can be used to inform judgements 
of the self, world and others.13 14 Impaired recall of 
specific memories is a key predictor of the first onset 
of depression15 and also of future depressive episodes 
in those with a history of recurrent depression (for 
meta-analysis see ref 16), although comparable studies 
examining the predictive effects of impaired generality 
or flexibility have yet to be carried out.
Figure 1 Flow chart of study design (Consolidated Standards of Reporting Trials diagram). All outcome and process measures 
will be completed at all time points. MemFlex, Memory Flexibility training. 
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A core feature of reduced flexibility is the chronic 
over-retrieval of autobiographical memories that are: 
(1) negative in emotional valence and (2) overgeneral in 
nature. Regarding valence, depressive risk is increased 
by a habitual and inflexible inclination towards nega-
tive memories, and subsequently, a neglect for posi-
tively valenced and neutrally valenced memories.17 
However, it is not simply that negative information is 
retrieved more readily, but that when positive informa-
tion is recalled, it is less vivid18 and therefore has an 
attenuated impact on affect, reducing the emotional 
benefits that are gained from recalling positive memo-
ries.19 In this way, biased memory retrieval can impair 
the ability to repair transient low mood.20 In addition, 
the absence of vivid, positive memories of oneself and 
a continual emphasis on negative autobiographical 
information reinforces the negative self-schemata that 
maintain and promote depression.21
Difficulties in intentional autobiographical retrieval 
also increases risk for depression. A tendency towards 
general memory recollection and reduced retrieval 
of specific memories is evident in those with current 
depression, however, the overgeneral retrieval style 
does not remit with depressive symptoms,11 suggesting 
that reduced specific recall is a durable cognitive 
marker for depression16 that may not be shifted by 
current psychological treatments,22 though this has not 
yet been well explored. Repeated recall of overgeneral 
summaries may promote depression by reinforcing 
overly general (negative) attributions regarding the 
self (eg, I always fail) and the world (eg, the world is an 
unfair place). Previous research has also demonstrated 
that impaired retrieval of specific memories impacts a 
number of intermediate factors that promote depres-
sion. Abstract and overgeneral memory recall intensi-
fies rumination,23 which in turn creates negative affect, 
impairs mood regulation, and is itself a risk factor for 
recurrent depression.24 Impaired retrieval of specific 
memories also reduces the ability to establish intimacy 
in social communication,25 impairs problem solving26 
and limits the ability to appropriately restrain the 
overly general, negative self-judgements that are char-
acteristic of depression.27
As reduced flexibility in the use of negative and over-
general memory retrieval styles both independently 
promote depression symptoms8 16 and may also interact 
with other risk factors (eg, stress28); to trigger a depressive 
episode, intervening to reduce bias and improve memory 
flexibility may thereby reduce depressive risk. There is 
some evidence to suggest a positive impact of targeting 
these factors individually, such as by reducing overgen-
eral memory through memory specificity training.29–31 
However, simultaneously targeting these factors may 
reduce compounded effects, and promote flexibility 
in the use of other depressogenic cognitive styles.32 In 
addition, explicitly training improved recall of positive, 
general memories (eg, of kindness, determination, caring 
relationships) may help to support reinitiation of the 
overly general, positive self-judgements that are associ-
ated with mental health (for review, see ref 33).
To this end, we have previously piloted a novel interven-
tion which aims to improve cognitive flexibility in those 
experiencing recurrent depression.34 MemFlex uses 
autobiographical memory as a modality to train negative 
and overgeneral processing styles. The workbook-based 
programme is presented in eight self-guided sessions 
completed over a 1-month period, and involves comple-
tion of memory retrieval exercises that aim to improve 
concrete, specific processing, thereby reducing overgen-
eral, abstract processing and improve access to neutral 
and positive emotional material, thereby reducing nega-
tive bias. In an initial uncontrolled trial with those in 
remission from MDD, MemFlex was effective in reducing 
overgeneral memory (d=0.48), rumination (d=0.29), and 
cognitive avoidance (d=0.18), and also improved social 
problem solving (d=0.55) from preintervention to postin-
tervention.34 An ongoing randomised controlled trial is 
comparing the effect of MemFlex to an active psycholog-
ical intervention for those experiencing a current major 
depressive episode (see ref35 for trial protocol). However, 
results from the uncontrolled trial suggest that MemFlex 
may not only prove beneficial for current symptoms of 
depression, but also for reducing cognitive risk factors for 
depressive relapse.
Preliminary evidence of an effect on multiple depres-
sive risk factors provides a solid foundation for a 
larger trial of MemFlex determining the efficacy of the 
programme in relapse prevention, against an active 
control group.36 In line with recommendations for the 
phase-based development and evaluation of novel inter-
ventions, we will complete an early-stage, randomised 
controlled platform trial with the primary aim of esti-
mating the likely effect size of MemFlex on measures of 
depressive relapse, which can then be used to inform a 
later-stage, fully powered trial. This study will therefore 
estimate the effect of MemFlex on the recurrence of 
depression over a 12-month period, relative to an active 
control condition—psychoeducation. We hypothesise 
effect sizes in favour of MemFlex, such that individuals 
completing MemFlex when they are currently remitted 
from depression will experience a greater number of 
depression-free days in the 12 months following work-
book completion and demonstrate a longer period of 




The design is a single-blind, participant-level randomised 
controlled trial comparing MemFlex to psychoeduca-
tion. All participants will provide informed consent to 
complete a 4-week programme, consisting of an initial 
face-to-face session, followed by eight self-guided work-
book sessions presenting either the psychoeducation 
or MemFlex materials. Participants will be assessed at 
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baseline, postintervention, at 6 months follow-up and at 
12 months follow-up.
Participants and recruitment
Inclusion criteria are a minimum age of 18 years and a 
primary diagnosis of MDD, as assessed using the Struc-
tured Clinical Interview for DSM Disorders (SCID37). On 
study entry, participants must not be currently experi-
encing a major depressive episode. That is, participants 
must be in partial or full remission from MDD, as indexed 
by the Longitudinal Interval Follow-up Evaluation 
(LIFE38) for the SCID. Additional exclusion criteria are 
prior completion of any autobiographical memory-based 
training programme, experience of another current 
mood disorder, psychosis, personality disorder or current 
drug, or alcohol dependence. Those experiencing signif-
icant cognitive impairment, as assessed through self-re-
port (via an open-ended question asking whether the 
individual has ever experienced an intellectual disability 
or traumatic brain injury), will also be excluded. Partic-
ipants may continue with any current recovery-main-
tenance medication or psychological interventions 
(eg, booster sessions, mindfulness practice) while partici-
pating in the study.
We will recruit through three avenues in Cambridge, 
UK. First, participants will be invited to contact us 
through advertisements in the general community 
(eg, posters in general practitioner surgeries) and the 
local newspaper. All those who contact us will be sent 
further information about the study, and invited to 
complete an initial telephone screening. We will also 
recruit from our database of participants with depres-
sion who are interested in taking part in research. All 
participants on this database have previously completed 
the SCID and meet criteria for MDD. These participants 
will be telephoned or emailed to make them aware of 
the study, and all those who express an interest in partic-
ipating will complete the LIFE to determine current 
depression and wider diagnostic status. Finally, we will 
recruit patients who have expressed an interest in partic-
ipating in research from local mental health services. 
Clinical care teams will be made aware of the study, and 
will be encouraged to ask their patients if they would 
like to take part in research. If the patient expresses an 
interest in research, their clinical care team will pass on 
our information sheet.
Participant allocation
Random allocation to condition using computer-gen-
erated, quasi-random numbers will completed by the 
trial statistician (PW), who is blind to study objectives. 
Once a participant has provided informed consent 
and completed the preintervention assessment, the 
researcher completing the initial session will open a 
sealed, opaque envelope to reveal condition allocation. 
This process is demonstrated in the Consolidated Stan-




We have previously piloted the MemFlex programme 
with individuals in remission from depression.34 The 
intervention will be delivered as per the pilot trial 
and the trial evaluating the intervention in those with 
current depression.35 The programme aims to improve 
the flexibility of autobiographical retrieval processes, 
to improve the ease with which individuals can access 
and move between specific and general personal 
memories, and to train away a bias towards negative 
memories. This is achieved through repeated comple-
tion of cued recall tasks which use positive and neutral 
cues. The training exercises are introduced in an initial 
face-to-face session with a researcher, and the partic-
ipant is then required to complete two times weekly 
sessions of training over a 4-week period. During the 
initial session, the researcher provides information 
about the role of autobiographical memory in depres-
sion, including the different types of autobiographical 
memories (eg, specific event memories, and the gener-
alised themes that link together a series of events) 
and their presumed role and importance in daily life. 
The rationale for MemFlex is then introduced. The 
researcher then assists the individual to complete prac-
tice exercises, and provides feedback and encourage-
ment to ensure that the individual understands the 
tasks. The session lasts between 45 and 60 min. The 
participant will also receive a telephone call from the 
researcher halfway through the time set to complete 
the workbook to answer any questions, and address any 
difficulties the individual may be having with the work-
book. The participant is also encouraged to contact 
the researcher with any questions about the workbook 
content.
The MemFlex workbook is separated into eight 
sessions. The early sessions of the workbook focus 
on reducing the bias towards negative and general 
memories experienced in depression by promoting 
the retrieval of both specific and general memories of 
neutral and positive valence. This involves repeated 
cued-recall exercises using neutral and positive cues. 
Next, the workbook encourages the individual to elab-
orate the specific emotional details attached to posi-
tive memories, again using repeated retrieval tasks. 
This seeks to improve the reduced vividness of posi-
tive memories experienced in depression.18 The final 
workbook sessions involve completion of exercises 
that require the participant to explicitly link specific 
event memories with a general theme, and in reverse, 
to identify individual event memories that form a 
general theme. To do this, individuals must explicitly 
switch between retrieving specific and general memo-
ries to the same cue, thereby promoting flexibility in 
movement between the different memory types. When 
completed with positive cues, this type of exercise also 
aims to promote positive generalisations about the self. 
Exercises are repeated throughout the workbook to 
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give participants practice in using the different skills. 
There are additional exercises at the end of the work-
book that the participant can choose to do after the 
study has ended. While participants are encouraged 
to continue to apply their new skills in their everyday 
life, completion of the additional workbook exercises 
is optional.
Psychoeducation
Participants in the psychoeducation condition will also 
attend a 45–60 min face-to-face session, followed by the 
completion of a workbook over a 4-week period. The 
initial session will provide information on the causes of 
depressive relapse, and the individual’s experience of 
relapse will be discussed between the researcher and 
participant. The eight-session workbook will then be 
introduced.
The psychoeducation workbook is a relapse-focused 
adaptation of that used in a previous trial for those with 
MDD.35 The workbook presents theory on different cogni-
tive and lifestyle factors that are associated with depres-
sion which may persist between depressive episodes, and 
promote the experience of low mood in the future. These 
include poor sleeping patterns, worry and perfectionism. 
After the relevant theory is explained, each component 
of the workbook will offer tips for improving each factor, 
and an exercise which encourages the participant to 
reflect on whether these factors occur in their life. Four 
multiple-choice questions are also asked at the end of 
each session to ensure participant engagement, and to 
match the completion of workbook exercises against the 
MemFlex condition. Interventions are matched for time 
burden.
Treatment integrity
Both workbooks are available from the corresponding 
authors on request, and will be made available online if 
their efficacy is demonstrated. Researchers will be trained 
and supervised by a clinical psychologist (CH) to admin-
ister the manualised initial sessions. Sessions will be 
audio-recorded, and 15% of these will rated for adher-
ence to the manual by a researcher independent from the 
project. At the end of the initial session, participants will 
complete the Credibility Expectancy Questionnaire—
Patient Version39 to index any difference in treatment 
expectations between the two intervention conditions. 
Progress on the workbook will be checked halfway 
through the 4 weeks provided for workbook comple-
tion. If the individual is behind on workbook comple-
tion, any difficulties in completing the workbook will be 
briefly addressed, and trial management records will be 
updated with an anticipated finish date. A member of the 
research team will call the individual the week before the 
anticipated finish date to set an appointment time for 
the postintervention assessment. To ensure adherence, 
the workbook will also be viewed at postintervention to 
ensure all materials have been attempted. The number of 
completed sessions will be recorded.
Measures
Cognitive target
We anticipate that the MemFlex programme will improve, 
and maintain improvement in, memory flexibility relative 
to psychoeducation. We will therefore administer the 
Autobiographical Memory Test with Alternating Instruc-
tions (AMT-AI8) at all assessments. The AMT-AI requires 
individuals to recall either specific or general memories 
in response to neutral, positive and negative cue words. 
Participants are asked to retrieve specific memories to 
a block of six cue words, general memories for a block 
of six cues and finally a block of 12 cues in which the 
individual must alternate between retrieval of specific 
and general memories. The cues are randomised to 
blocks, and the order in which the blocks are presented 
is also randomised. The main outcomes are the number 
and proportion of correct responses for each block (ie, 
specific, general, alternating).
Primary clinical outcomes
The primary clinical outcomes are number of depres-
sion-free days from postintervention to 12-month 
follow-up, and number of days until depressive relapse, 
both according to the LIFE.
Secondary clinical outcomes
The secondary clinical outcomes are depressive status at 
12-month follow-up, again measured using the LIFE and 
symptoms of depression at 12-month follow-up as indexed 
on the Beck Depression Inventory II (BDI-II40).
Additional process measures
We have previous evidence to suggest that MemFlex will 
impact rumination, social problem solving and cognitive 
avoidance in samples remitted from depression.34 We 
will therefore assess whether these factors may mediate 
the impact of MemFlex on our primary and secondary 
outcomes. Rumination will be measured using the Rumi-
nation Response Scale,41 cognitive avoidance will be 
measured using the Cognitive Avoidance Questionnaire42 
and social problem solving will be indexed on the short 
version of the Means-Ends Problem-Solving (MEPS) task.43 
We will also assess verbal fluency using the Verbal Fluency 
Task44 to determine whether the programme impacts 
the fluent retrieval of verbal information. Each of these 
measures possesses adequate psychometric properties 
and has been previously used in evaluation of autobi-
ographical memory interventions.7 34 35 Parallel forms 
of these measures will be counterbalanced and adminis-
tered at all time points.
Methodological aspects
Power analysis
As this is an exploratory, early-stage randomised 
controlled platform trial (in accordance with recom-
mendations for the evaluation of complex interven-
tions; Medical Research Council (MRC), 2000), we aim 
to generate estimates of the range of likely effect sizes of 
MemFlex (relative to psychoeducation) on our primary 
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clinical outcomes. This can then be used to inform a 
power calculation for a fully powered later-phase trial. 
Our prior experience with autobiographical memo-
ry-based interventions for depression (eg, refs 29 34 35 45) 
suggests that 25 participants per condition will provide a 
plausible range of point estimates. Given the long-term 
follow-up we implement, we aim to recruit 35 participants 
in each condition (70 participants in total) to allow for up 
to 25% attrition.
Data collection and blinding
Participants will be assessed at baseline, and then again 
at postintervention, and at 6-month and 12-month 
follow-ups after the intervention has been completed. 
All sessions will be completed at the MRC Cognition and 
Brain Sciences Unit in Cambridge, UK, except in the case 
that a participant moves away from Cambridge before the 
completion of all assessments. In these cases, 6-month and 
12-month follow-up assessments may be completed over 
the telephone. As the AMT-AI is unable to be completed 
over the telephone, it will not be administered at follow-up 
for these participants. Research staff completing the 
assessments will be supervised by a clinical psychologist 
(CH) and inter-rater reliability will be completed for the 
AMT-AI and MEPS to ensure data quality and protection 
from bias. Bias will also be protected against at all assess-
ments through use of research staff whom are blind to 
experimental condition.
Statistical analysis plan
The trial statistician is blind to study objectives, and will 
complete all analyses in accordance with CONSORT 
standards. No interim analyses are planned during 
data collection. Between-group difference on our 
primary clinical outcome of number of depression-free 
days will be analysed using an independent samples 
t-test, or analysis of covariance if necessary to account 
for any baseline differences. Time to depressive 
relapse will be compared between groups using Cox 
regression survival analysis. Analysis of our cognitive 
target variable, secondary clinical outcomes and addi-
tional process measures will be analysed using analysis 
of variance (ANOVA) with time (pre, post, 6 and 12 
follow-up) as a within-subjects factor, and condition 
(MemFlex, psychoeducation) as a between subjects 
factor. Any baseline differences in the cognitive target, 
symptom severity on the BDI-II, concurrent treatment 
or demographics will be covaried in analyses. Diag-
nostic status at 12-month follow-up will analysed using 
logistic regression. Residual depression symptoms and 
number of previous episodes (as an index of depres-
sion severity), and score on the AMT-AI (as an index 
of bias severity) at preintervention will be explored as 
moderators of treatment efficacy by computing product 
variables that will be analysed using linear regression. 
Finally, we will explore mechanisms of change by deter-
mining whether intervention effects are mediated by 
change on the AMT-AI and the other process measures. 
Indirect effects will be analysed using bootstrapped 
samples in the Process statistical package. Intent-to-
treat analysis will be used for those lost to attrition by 
using multiple imputation to account for missing data. 
The number of imputed datasets will approximate the 
percentage of missing data.46 Any exploratory, per-pro-
tocol analyses will use data from participants who have 
completed six out of the eight workbook sessions. 
Exploratory ANOVAs will also be completed to explore 
between-group difference in pre-to-post intervention 
change on the separate AMT-AI blocks, to determine 
whether MemFlex may have a larger impact on specific, 
categoric or alternating recall.
trial management
The trial management committee will be formed by TD, 
CH and trial statistician (PW). The trial coordinator 
(CH) will complete data checks to ensure data quality.
Ethics and dissemination
All individuals will provide informed consent prior to 
participation, and Medical Research Council, National 
Health Service and professional ethical guidelines will 
be adhered to throughout the study. Any necessary 
amendments to this protocol will be published in the 
trial manuscript. No restrictions have been placed on 
the publication of results. In addition to publication of 
the trial paper, results will be shared in written form to 
trial participants, and through seminars to clinicians 
and the general public.  
safety aspects
In the unlikely occurrence of adverse events, the 
Medical Research Council’s structured risk assessment 
protocols will be used to manage risk. All risk issues will 
be managed by the trial coordinator (CH), in consul-
tation with TD, both of whom are clinical psychologists 
experienced in treatment of depression. Any adverse 
events will be reported to the research ethics committee, 
and will be reported in the trial manuscript.
Confidentiality and access to data
Only the trial coordinator and trial statistician will have 
access to the final dataset. Data will be securely stored 
in de-identified form on-site, and in encrypted elec-
tronic format. Personally identifiable information will 
be stored separately to the trial data, and will only be 
accessible via a dedicated access server. Once the data 
have been analysed and the trial is published, the final 
dataset will be deposited in de-identified form into the 
research unit’s online data repository, along with the 
used statistical code.
trial registration
The trial protocol was registered online on 25 November 
2015 at  ClinicalTrials. gov (identifier NCT02614326), 
with recruitment planned to open in January 2016. The 
first participant was recruited on 18 January 2016.
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dIsCussIon
Major depression is predicted to be the largest global 
burden of disease by 2030.47 Reducing the recurrence 
of depression will therefore be a key issue for the 
coming years. This study will estimate the effect of a 
novel intervention, MemFlex, which aims to reduce 
negative and overgeneral memory biases, and thereby 
risk of depressive relapse. In simultaneously targeting 
these factors, the programme may reduce both direct 
and compounded effects on depressive relapse. This 
trial aims to estimate the range of likely effects of 
MemFlex, to provide a platform for a later-stage, fully 
powered trial, and to begin to explore mechanisms of 
change. If effective, MemFlex may hold promise as a 
low-cost and low-intensity option for reducing depres-
sive relapse as the self-guided, workbook format of 
the programme would be simple and cost-effective to 
provide to individuals on discharge from a treatment 
service, or potentially as an adjunct to complex inter-
ventions such as cognitive-behavioural therapy. As the 
pressure that depression places on healthcare systems 
is expected to increase,48 further development of 
low-cost relapse prevention programmes will be vital in 
improving access to psychological services and quality 
of life for those experiencing chronic and recurrent 
depression.
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